CTOR Stock Forecast: Citius Oncology, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Citius Oncology, Inc. hold a median 12-month price target of $4 — +575.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CTOR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Citius Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (81): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Citius Oncology, Inc. — and when they’d sell — is the membership.
CTOR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTOR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +575.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2025 | Maxim Group | Upgrade | Buy | $6.00 |
| 23 May 2025 | Maxim Group | Downgrade | Hold | — |
| 27 Nov 2024 | Maxim Group | Initiates | Buy | — |
| 13 Aug 2024 | EF Hutton | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CTOR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Citius Oncology, Inc. (CTOR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.8×
- Price / sales
- 9.8×
- Price / book
- 1.6×
- EV / EBITDA
- −2.4×
Cheaper than 84% of US stocks
Cheaper than 14% of US stocks
Cheaper than 54% of US stocks
Cheaper than 73% of US stocks
- Revenue growth (YoY)
- −57.7%
- Earnings growth (YoY)
- —
- Gross margin
- 80.3%
- Operating margin
- −1716.2%
- Net margin
- 0.0%
Higher than 4% of US stocks
Higher than 91% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
- Return on equity
- −119.9%
- Return on assets
- −28.3%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CTOR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTOR appears on the weeks it earns a place.
Frequently asked questions about CTOR stock
What is the CTOR stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Citius Oncology, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTOR stock a buy right now?
Of the 1 analysts covering Citius Oncology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Oncology, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTOR?
As at 1 Aug 2026, Citius Oncology, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).
Will CTOR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +575.3% from the last close, and Ticker Nerd's factor model ranks Citius Oncology, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTOR stock forecast for 2030?
No analyst covering Citius Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
What does Citius Oncology, Inc. do?
Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment.
About Citius Oncology, Inc.
Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. Citius Oncology's significance in the market revolves around its commitment to advancing cancer therapeutics, which is a critical area due to the disease's widespread impact globally. As a clinical-stage entity, the company plays a crucial role in the pipeline of medical innovation, contributing to potential future options for cancer care. Citius Oncology partners with research institutions and other biopharmaceutical enterprises to push the boundaries of standard oncology treatments. This makes it an influential player in the biotechnology and healthcare sectors, aligning with a broader industry goal to improve patient outcomes in oncology.
CEO Mr. Leonard L. Mazur · United States · https://citiusonc.com/overview/default.aspx